PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 29 PubMed articles · model: gemma4:31b
Summary
Background
Mechanism of action
Clinical evidence
A prospective randomised phase III study (CICA-RT) evaluated the efficacy of Cicaderma (containing Centella asiatica) in preventing grade ≥ 2 radiodermatitis after post-operative breast irradiation [PMID:37441546].
Evidence summary
PubMed sources
- 1.PMID: 32100931 (2020) — Bioactive ingredients in Korean cosmeceuticals: Trends and research evidence. · Journal of cosmetic dermatology
- 2.PMID: 24137203 (2013) — Effect of herba centellae on the expression of HGF and MCP-1. · Experimental and therapeutic medicine
- 3.PMID: 37441546 (2023) — Cicaderma® in radiation-related dermatitis of breast cancer: Results from the multicentric randomised phase III CICA-RT. · Clinical and translational radiation oncology
- 4.PMID: 32186007 (2019) — Jixuecao (Herba Centellae Asiaticae) alleviates mesangial cell proliferation in IgA nephropathy by inducing mitofusin 2 expression. · Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan